TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancersTushar D. Nichakawade, Suman Paul, Surojit Sur et al.|Nature|2024Cited by 43
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J. Mog, Shibin Zhou, Nikita Marcou et al.|Science Translational Medicine|2024Cited by 23
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptorsAdrian Johnston, Denis Wirtz, Gretchen M. Alicea et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 14
Abstract LB095: Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigenBrian J. Mog, Shibin Zhou, Sarah R. DiNapoli et al.|Cancer Research|2023Cited by 1
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLNour Sabiha Naji, Theodoros Karantanos, Taha Ahmedna et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1